Assessing the Effectiveness of Montelukast Sodium in Managing Pulmonary Infections in Lung Cancer Patients

Objective:To investigate the efficacy of montelukast sodium in the treatment of lung cancer patients with pulmonary infections.Methods:A total of 330 patients diagnosed with lung cancer and pulmonary infection,who were admitted to the First Affiliated Hospital of Xi’an Medical University from 2020 to 2022,were selected as research subjects.They were randomly divided into two groups:a control group receiving conventional treatment and an observation group receiving conventional treatment combined with montelukast sodium.Each group consisted of 165 cases.The time required for clinical symptom improvement,the resolution of lung infection signs,and the levels of serum inflammatory factors before and after treatment were compared between the two groups.Results:The observation group exhibited significantly faster improvement in clinical symptoms compared to the control group(P<0.001).ELISA assays were conducted to detect the expression levels of IL-1β,IL-6,IL-8,and TNF-αin the serum of both groups at 1 week and 2 weeks into the treatment.The results indicated that,as the treatment progressed,the observation group displayed significantly lower levels of the four serum inflammatory factors compared to the control group(P<0.001).Conclusion:Montelukast sodium demonstrates efficacy in the treatment of patients with lung cancer complicated by pulmonary infections.These findings suggest its potential for further verification and clinical application.

Montelukast神经保护作用及机制研究进展

半胱氨酰白三烯(cysteinylleukoriencs,Cys LTs)是中枢神经系统的重要炎症介质,通过激动Cys LT受体而产生炎症效应。目前研究表明,Cys LT1受体拮抗剂Montelukast对体外和体内实验性脑损伤,特别是对脑缺血以及阿尔茨海默病(Alzheimer’sdisease,AD)和帕金森病(Parkinson’s disease,PD)等中枢退行性疾病具有良好的神经保护作用。本文对Montelukast在脑缺血,中枢退行性疾病以及其他脑损伤中的保护作用进行综述,并讨论Montelukast神经保护作用的分子机制。

低剂量鱼藤酮诱导BV2细胞IL-6产物及montelukast的作用

目的在体外帕金森病（Parkinson＇s disease,PD）模型观察低剂量鱼藤酮诱导的BV2小胶质细胞白介素6（IL-6）生成及montelukast的作用。方法以PD诱导因子鱼藤酮处理小鼠小胶质细胞系BV2细胞。Western blot方法检测BV2细胞前炎症细胞因子IL-6蛋白表达,ELISA方法检测BV2细胞IL-6释放。观察Cys LT1R拮抗剂montelukast对鱼藤酮诱导的小胶质细胞IL-6的影响。结果低剂量鱼藤酮（0.3～3 n M）浓度依赖性地增加IL-6蛋白表达;以鱼藤酮（3 n M）处理细胞1～24h,时间依赖性的诱导IL-6释放增加。Cys LT1R拮抗剂montelukast降低鱼藤酮增高的BV2细胞IL-6水平。结论低剂量鱼藤酮诱导小胶质细胞前炎症细胞因子IL-6增加,montelukast抑制鱼藤酮诱导BV2细胞效应。

Isolation and Characterization of S-Enantiomer in Montelukast

A simple and rapid Supercritical Fluid Chromatography (SFC) Method has been developed to isolate and characterize the S-Isomer of Montelukast by using normal phase Amylose based AS-H with 250 mm × 30 mm, 5 microns column using a mobile phase system containing super critical fluid carbon dioxide (CO2) and the percentage of 2-Propanol as a mobile phase (85:15) and detection at 230 nm. The isolated S-Isomer was characterized by using FT-IR, ESI-MS, HPLC and 1H NMR. The purity of isolated S-Isomer is about 98%.

Effects of methylprednisolone combined with montelukast on immune function and cytokines in children with recurrent Henoch-Schonlein purpura

Objective:To study the effects of methylprednisolone combined with montelukast on immune function and cytokines in children with recurrent Henoch-Schonlein purpura.Methods:Children who were diagnosed with recurrent Henoch-Schonlein purpura in Zigong Third People's Hospital between September 2015 and August 2017 were selected as the research subjects and randomly divided into the intervention group who received methylprednisolone combined with montelukast therapy and the control group who received hydrocortisone therapy. The levels of Th1/Th2 and Th17/Treg immunity indexes in peripheral blood as well as cytokines in serum were measured before treatment as well as 4 and 8 weeks after treatment.Results: 4 weeks and 8 weeks after treatment, Th1 and Treg cell contents as well as T-bet and FoxP3 mRNA expression in peripheral blood of both groups of patients were significantly higher than those before treatment whereas Th2 and Th17 cell contents as well as GATA-3 and RORγt mRNA expression in peripheral blood and NF-κB, OPN, IL-33, MK and HMGB1 contents in serum were significantly lower than those before treatment, and Th1 and Treg cell contents as well as T-bet and FoxP3 mRNA expression in peripheral blood of intervention group were significantly higher than those of control group whereas Th2 and Th17 cell contents as well as GATA-3 and RORγt mRNA expression in peripheral blood and NF-κB, OPN, IL-33, MK and HMGB1 contents in serum were significantly lower than those of control group.Conclusion: methylprednisolone combined with montelukast treatment of recurrent Henoch-Schonlein purpura can regulate the immune function and inhibit the cytokine secretion.

Analysis of montelukast in combined with extended care applied in children with bronchial asthma

Objective:To explore the application effect of montelukast in combined with extended care in children with bronchial asthma.Methods:A total of 80 children with bronchial asthma who were admitted in our hospital from May, 2014 to May, 2015 were included in the study and randomized into the observation group and the control group with 40 cases in each group. The patients in the two groups were given routine treatments and pidotimod granules. On this basis, the patients in the observation group were given additional montelukast and extended care after discharge. The fasting peripheral venous blood before treatment and 3 months after treatment in the two groups was collected. The immunoturbidimetry was used to detect the serum IgA, IgG, and IgM. The pulmonary function detector was used to detect FEV1, FVC, and PEF. Follow-up visits were paid to record the asthma attack times, readmission rate, re-first aid rate, and first aid times after discharge within 1 year.Results:IgA and IgG after treatment in the two groups were significantly elevated (P<0.05), while IgM had no significant change (P>0.05). The elevated degree of IgA and IgG in the observation group was significantly greater than that in the control group (P<0.05). FEV1 (L), FVC (L), and PEF (L/min) after treatment in the two groups were significantly elevated when compared with before treatment (P<0.05). The elevated degree of FEV1, FVC, and PEF in the observation group was significantly greater than that in the control group (P<0.05). The asthma attack times, readmission rate, re-first aid rate, and first aid times after discharge within 1 year in the observation group were significantly lower than those in the control group (P<0.05).Conclusions:The routine treatment in combined with montelukast can better effectively control the symptoms in children with asthma, and improve the pulmonary function. After discharge, the extended care can be more beneficial to control the asthma attack, and enhance the living quality.

Evaluation of the cytokine levels and immune response status of montelukast, loratadine and tanshinone combination therapy for Henoch-Schonlein purpura

Objective:To evaluate the cytokine levels and immune response status of montelukast, loratadine and tanshinone combination therapy for Henoch-Schonlein purpura.Methods: A total of 80 patients with Henoch-Schonlein purpura who were treated in Ankang Central Hospital between May 2014 and January 2017 were collected and divided into montelukast group, loratadine group, tanshinone group and combined treatment group according to the random number table, 20 cases in each group. Serum levels of inflammatory factors, Th17/Treg cellular immunity indexes before and after treatment were compared among four groups of patients.Results: Before treatment, differences in serum levels of inflammatory factors and Th17/Treg cellular immunity indexes were not statistically significant among four groups of patients. After treatment, serum HMGB1, IL-8, IL-14, IL-23 and IL-33 levels in combined treatment group were lower than those in montelukast group, loratadine group and tanshinone group;serum IL-17 level was lower than that in montelukast group, loratadine group and tanshinone group while IL-10 and TGF-β levels were higher than those in montelukast group, loratadine group and tanshinone group.Conclusions: Montelukast, loratadine and tanshinone combination therapy for Henoch-Schonlein purpura helps to reduce systemic inflammatory response and balance Th17/Treg cell immunity.

Effect of glucocorticoid inhalation combined with oral montelukast on airway function and serum inflammatory cytokines in patients with bronchial asthma

Objective:To study the effect of glucocorticoid inhalation combined with oral montelukast on airway function and serum inflammatory cytokines in patients with bronchial asthma. Methods: 138 patients diagnosed with bronchial asthma in our hospital between August 2014 and February 2016 were selected and randomly divided into two groups (n=69), observation group received oral montelukast combined with symbicort inhalation treatment, and control group received symbicort inhalation treatment. 3 months and 6 months after treatment, spirometer was used to measure the airway function parameters, and enzyme-linked immunosorbent assay kits were used to determine Th1/Th2, Treg/Th17 and Th9/cTfh cytokine content. Results:3 months and 6 months after treatment, 1 second (FEV1)/forced vital capacity (FVC), tidal expiratory flow at 25%, 50%and 75%of tidal volume (TEF25%, TEF50%and TEF75%) of observation group were significantly higher than those of control group (P<0.05);serum interleukin-2 (IL-2), interferon-γ (IFN-γ), tumor necrosis factor (TNF-α), IL-10 and transforming growth factor (TGF-β) levels of observation group were significantly higher than those of control group (P<0.05) while IL-4, IL-6, IL-17, IL-22, IL-9 and IL-21 levels were significantly lower than those of control group (P<0.05). Conclusions:Montelukast combined with conventional inhalation treatment of bronchial asthma can more effectively improve the airway function and inhibit the airway inflammatory response mediated by Th1/Th2, Treg/Th17 and Th9/cTfh imbalance.

Effects of montelukast sodium combined with budesonide on lung function, inflammatory factors and immunoglobulin levels in children with asthma

Objective: To investigate the effects of montelukast sodium combined with budesonide on pulmonary function, inflammatory factors and immunoglobulin in children with asthma. Methods: A total of 100 children with asthma treated in our hospital from May 2013 to November 2016 were randomly divided into control group and observation group. In the control group, budesonide inhalation therapy was given. On the basis of the control group, montelukast sodium treatment was given, pulmonary function, inflammatory factors and immunoglobulin levels in the two groups before and after treatment were measured. Results:Compared with before treatment, the levels of FEV1%, FEF50%, FEF25% and PEF% in the two groups were significantly increased, those in the observation group were higher than in control group;compared with before treatment, IL-10 levels were significantly increased, TNF-α and IL-8 levels were significantly decreased in the two groups after treatment, moreover those in the observation group IL-10 levels were significantly higher than the control group, TNF-α and IL-8 were significantly lower than those in the control group, the difference was statistically significant;Compared with before treatment, IgA and IgM levels were significantly increased in both groups after treatment, IgE levels were significantly decreased, and IgA and IgM levels in the observation group were significantly higher than in the control group, IgE levels were significantly lower than the control group, the difference was statistically. Conclusion: Montelukast sodium combined with budesonide can effectively reduce the inflammation level of children with asthma, improve lung function, enhance immunity, the effect is significant, it is worth further clinical application.

Comparison of FT-NIR Transmission and HPLC to Assay Montelukast in Its Pharmaceutical Tablets

For several years, near-infrared spectroscopy (NIRS) has become an analytical technique of great interest for the pharmaceutical industry, particularly for the non-destructive analysis of dosage forms. The goal of this study is to show the capacity of this new technique to assay the active ingredient in low-dosage tablets. NIR spectroscopy is a rapid, non-destructive technique and does not need any sample preparation. A prediction model was built by using a partial least square regression fit method. The NIR assay was performed by transmission. The results obtained by NIR spectroscopy were compared with the conventional HPLC method for Montelukast tablets produced by Sigma pharmaceutical corp. The study showed that Montelukast tablets can be individually analyzed by NIR with high accuracy. It was shown that the variability of this new tech- nique is less important than that of the conventional method which is the HPLC with UV detection.

Method Development and Validation for Simultaneous Estimation of Montelukast Sodium and Desloratadine by RP-HPLC

A novel, precise, accurate, rapid and cost effective isocratic reverse-phase high performance liquid chromatographic (RP-HPLC) method was developed, optimized and validated for the simultaneous estimation of Montelukast Sodium (MON) and Desloratadine (DES) in pharmaceutical dosage forms. The drugs were estimated using Hypersil BDS C18 (250 mm × 4.6 mm I.D., 5 μ particle size) column. The mobile phase composed of orthophosphoric acid and water in the ratio of 20:80 v/v, at a flow rate of 1.0 ml/min was used for the separation. Detection was carried out at 280 nm. The linearity range obtained was 10 - 30 μg/ml for MON and 5 - 15 μg/ml for DES with retention times of 2.929 min and 4.439 min for MON and DES respectively. The correlation coefficient values were found to be 0.999. Precision studies showed % RSD values less than 2% for both the drugs in all the selected concentrations. The percentage recoveries of MON and DES were in the range of 99.59% - 99.82% and 99.60% - 99.80% respectively. The limit of detection (LOD) and limit of quantification (LOQ) were 0.176 μg/ml, 0.587 μg/ml for MON and 0.087 μg/ml, 0.292 μg/ml for DES respectively. The method was validated as per the International Conference on Harmonization (ICH) guidelines. The proposed validated method was successfully used for the quantitative analysis of commercially available tablet dosage forms.

Therapeutic effect of montelukast sodium + methylprednisolone +azithromycin therapy for patients with mycoplasma pneumonia

Objective: To explore the therapeutic effect of montelukast sodium + methylprednisolone+ azithromycin therapy for patients with mycoplasma pneumonia. Methods: A total of 88 patients with mycoplasma pneumonia who were treated in our hospital between July 2015 and June 2017 were collected and divided into group A (oral azithromycin), group B (oral azithromycin + methylprednisolone), group C (oral azithromycin + montelukast sodium) and group D (oral montelukast sodium + methylprednisolone + azithromycin), and they were continuously treated for 1 week. The differences in therapeutic effect, systemic inflammatory response and stress response were compared among the four groups of patients. Results:After 1 week of treatment, the overall response rate of group D was higher than that of group A, group B and group C, and the overall response rate of group B and group C were higher than that of group A respectively;serum inflammatory factors C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor α (TNF-α), cortisol (COR), malondialdehyde (MDA) and advanced oxidation protein product (AOPP) levels of group D were lower than those of group A, group B and group C, and serum CRP, IL-6, TNF-α, COR, MDA and AOPP levels of group B and group C were lower than those of group A respectively. Conclusion:Montelukast sodium + methylprednisolone + azithromycin therapy can significantly improve the therapeutic effect and inhibit the systemic inflammatory and stress response in patients with mycoplasma pneumonia.

Effects of budesonide inhalation and montelukast on airway function and serum inflammatory factors in children with asthma

Objective: To investigate the effect of budesonide and montelukast on airway function and serum inflammatory factors in children with asthma. Methods: A total of 72 children with bronchial asthma were selected as the subjects, and randomly divided into the observation group (36 cases) and the control group (36 cases). The children in the control group were treated with Budesonide Aerosol, and the observation group was treated with montelukast sodium on the basis of the control group. The airway function and the level of inflammatory factors were detected and compared between the two groups. Results: Before treatment, there was no significant difference in TEF25%, TEF50%, TEF75% and FEV1/FVC between the two groups;After treatment, the TEF25%, TEF50%, TEF75% and FEV1/FVC of the two groups were improved before treatment, and the indexes in the observation group were higher than those in the control group, the difference was statistically significant. Before treatment, the IL-4, IL-6, IL-8, IL-17, TNF- alpha levels in the two groups were not statistically different;After treatment, the levels of IL-4, IL-6, IL-8, IL-17 and TNF- in the two groups were lower than those before the treatment, and the indexes in the observation group were lower than those in the control group, and the differences were statistically significant. Conclusion: Budesonide inhalation combined with montelukast can improve the airway function and inflammatory factors in children with asthma.

Effects of montelukast sodium combined with pidotimod on acute phase protein and immune function in children with acute bronchitis

Objective: To observe the effects of montelukast sodium combined with pidotimod on acute phase protein (APP) and indexes of immunologic function in pediatric acute bronchitis treatment. Methods: A total of 180 cases children with acute bronchitis acted as research objects were randomly divided into control group (n=65) and observation group (n=63). On the basis of conventional therapy, control group was treated by plus pidotimod. On this base, observation group was treated with montelukast sodium. The changes of acute phase proteins (CRP, HP, a1-AAG and CER) and immune function (CD3+, CD4+, CD8+ and CD4+/CD8+) levels before and after treatment were observed after 2 months. Results: Before treatment, CRP, HP, a1-AAG, CER, CD3+, CD4+, CD8+ and CD4+/CD8+ levels of two groups had no statistically significant difference;CRP, HP, a1-AAG, CER, and CD8+ levels of control and observation groups decreased significantly after treatment, the decreases of observation group were more obvious than that of control group, and the levels after treatment were significantly lower than that of control groups. The levels of CD3+, CD4+ and CD4+/CD8+ in two groups after treatment were significantly higher than those before treatment. For observation group, the levels of CD3+, CD4+ and CD4+/CD8+ increased more significantly after treatment, which were significantly higher than that of the control group. Conclusion: Using Montelukast sodium combined with pidotimod can effectively reduce the children's acute phase protein levels, improve immune function, which has clinical value for the treatment of children with acute bronchitis.

Connection between dermatomyositis and montelukast sodium use: A case report

BACKGROUND Montelukast or Singulair is a leukotriene receptor antagonist that reduces inflammation and relaxes the smooth muscles.It is known to be a safe and tolerable drug;nevertheless,it might be associated with several mild to severe adverse effects,one of which is dermatomyositis.Dermatomyositis is a rare acquired autoimmune myositis of unknown cause affecting adults and children.The literature has infrequently reported the association between dermatomyositis and montelukast use.CASE SUMMARY The current study reports a case of a 48-year-old black woman with a previous history of bronchial asthma and allergic rhinosinusitis who presented with typical signs and symptoms of dermatomyositis which were confirmed by investigations.Before developing dermatomyositis,the patient was prescribed montelukast for atopy and consumed the drug for five months.After administration of prednisolone,the patient had a significant improvement and is still being followed up.CONCLUSION Even though montelukast is widely used and believed to be a safe drug for managing several conditions,the present case report highlights the possibility of adverse effects of montelukast.Therefore,future studies with advanced study designs are highly recommended to investigate the association between dermatomyositis and montelukast use.

Evaluating the effect of montelukast tablets on respiratory complications in patients following blunt chest wall trauma:A double-blind,randomized clinical trial

Purpose:Patients with multiple traumas are at high risk of developing respiratory complications,including pneumonia and acute respiratory distress syndrome.Many pulmonary complications are associated with systemic inflammation and pulmonary neutrophilic infiltration.Leukotriene-receptor antagonists are anti-inflammatory and anti-oxidant drugs subsiding airway inflammation.The present study investigates the effectiveness of montelukast in reducing pulmonary complications among trauma patients.Methods:This randomized,double-blind,placebo-control trial was conducted in patients with multiple blunt traumas and evidence of lung contusion detected via CT scan.We excluded patients if they met at least one of the following conditions:< 16 years old,history of cardiopulmonary diseases or positive history of montelukast-induced hypersensitivity reactions.Patients were allocated to the treatment (10 mg of montelukast) or placebo group using permuted block randomization method.The primary measured outcome was the volume of pulmonary contusion at the end of the trial.The secondary outcomes were intensive care unit and hospital length of stay,ventilation days,multi-organ failure,and the in-hospital mortality rate.Results:In total,65 eligible patients (treatment = 31,placebo = 34) were included for the final analysis.The treatment group had more pulmonary contusion volume (mean (SD),mm3) at the right (68726.97 (93656.54)vs.59730.27 (76551.74)) and the left side (67501.71 (91514.04)vs.46502.21 (80604.21)),higher initial C-reactive peptide level (12.16 (10.58)vs.10.85 (17.87)) compared to the placebo group,but the differences were not statistically significant (p > 0.05).At the end of the study,the mean (SD) of pulmonary contusion volume (mm3) (right side = 116748.74 (361705.12),left side = 64522.03 (117266.17)) of the treatment group were comparable to that of the placebo group (right side = 40051.26 (64081.56),left side = 25929.12 (47417.13),p = 0.228 and 0.082,respectively).Moreover,both groups have statistically similar hospital (mean (SD),days) (10.87 (9.83)vs.13.05 (10.12)) and intensive care unit length of stays (mean (SD),days) (7.16 (8.15)vs.7.82 (7.48)).Of note,the frequency of the in-hospital complications (treatmentvs.control group) including acute respiratory distress syndrome (12.9%vs.8.8%,p = 0.71),pneumonia (19.4%vs.17.6%,p = 0.85),multi-organ failure (12.9%vs.17.6%,p = 0.58) and the mortality rate (22.6%vs.14.7%,p = 0.41) were comparable between the groups.Conclusion:Administrating montelukast has no preventive or therapeutic effects on lung contusion or its complications.

孟鲁司特钠单用、布地奈德/福莫特罗单用及两者联用治疗对儿童咳嗽变异型哮喘的疗效比较

目的本研究旨在比较孟鲁司特钠(Mon)单用、布地奈德/福莫特罗(BF)单用及两者联用治疗儿童咳嗽变异型哮喘(CVA)的疗效。方法选取2021年6月至2023年6月北京市海淀医院诊治的CVA患儿为研究对象。根据治疗方案,将CVA患儿分为Mon组、BF组和联合组。观察治疗8周后的治疗总有效率(TER)、不良反应发生率(TAER)、咳嗽症状评分[日间咳嗽症状评分(DCSS)和夜间咳嗽症状评分(NCSS)]、免疫功能[肿瘤坏死因子-α(TNF-α)、白细胞介素-4(IL-4)和免疫球蛋白E(IgE)]、肺功能[第1秒用力呼出气体容量(FEV_(1))、肺活量(FVC)和呼气峰值流速(PEF)]和血清嗜酸性粒细胞计数(EOS)。结果共选取180例CVA患儿,Mon组62例,BF组60例,联合组58例。治疗后,3组TER、TAER、DCSS、NCSS、血清TNF-α、血清IL-4和血清IgE水平差异无统计学意义(P>0.05)。联合组患儿FEV_(1)、FVC和PEF显著高于Mon组和BF组(P<0.05),EOS显著低于Mon组和BF组(P<0.05);而Mon组和BF组FEV1、FVC、PEF和EOS学差异无统计学意义(P>0.05)。结论Mon或BF可有效改善CVA患儿咳嗽症状和免疫功能,其镇咳作用和抗炎作用同Mon和BF联用相似。此外,Mon和BF联用可进一步改善CVA患儿肺功能,减少血清EOS水平。